Related Articles
Managing Clozapine Adverse Events
PSYCHIATRY EDUCATION FORUM ACADEMY’S MANAGING CLOZAPINE ADVERSE EVENTS UNDERSTANDING THE BASICS & BEYOND Introduction: Clozapine was FDA-approved for treatment-refractory schizophrenia in 1989 and has remained…
Augmentation Strategies for Major Depressive Disorder
PSYCHIATRY EDUCATION FORUM ACADEMY’S LECTURE SERIES: MAJOR DEPRESSIVE DISORDER: 10 AUGMENTATION STRATEGIES Introduction Psychiatry Education Forum Academy continues to provide high-quality, evidence-based & practice-oriented discussions…
LYBALVIâ„¢: New Medication FDA Approved for Schizophrenia & Bipolar Disorder
June 01, 2021 Today FDA approved LYBALVI for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed…
Journal Club #2: Omega-3 Fatty Acids for MDD Treatment (ISNPR Practice Guidelines)
Today we posted the following second journal club in PEFA Journal Club’s discussion series: Journal Club #2: International Society for Nutritional Psychiatry Research Practice Guidelines…
PEFA Journal Club: Updated Schedule Released
Psychiatry Education Forum’s Journal Club is an additional feature for PEF Academy’s members. All academy members will be automatically enrolled in this journal club. Here…